Authorization

Poxel Announces Symposium Presentation for Imeglimin at 55th Annual Meeting of the European Association for the Study of Diabetes

POXEL S.A. (Euronext a?? POXEL a?? FR0012432516), a biopharmaceutical company dedicated to the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), announced today that it will be attending and presenting a session at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD), held at the Fira Barcelona Gran Via conference center in Barcelona, Spain from September 16 a?? 20, 2019.


The session will be chaired by leading academic diabetes expert, Ralph DeFronzo, M.D., Professor of Medicine and Chief of the Diabetes Division at UT Health San Antonio and Deputy Director of the Texas Diabetes Institute, part of University Health System, San Antonio, Texas. The purpose of the session will be to discuss the therapeutic potential of Poxela??s lead drug candidate, Imeglimin, a novel treatment approach for type 2 diabetes in various patient populations, and to present the detailed Phase 3 TIMES 1 results in Japanese patients. The session will be followed by an open Q&A.


Session Details


Session Title: Imeglimin: a first-in-class oral medication with a unique mechanism of action targeting mitochondrial bioenergetics


Speakers and Lecture Titles:


Ralph DeFronzo, M.D., Professor of Medicine and Chief of the Diabetes Division at UT Health San Antonio and Deputy Director of the Texas Diabetes Institute, part of the University Health System, San Antonio, Texas: The role of mitochondrial dysfunction in the pathophysiology of diabetes (Oral Presentation # S22.1)
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Декабрь 2019    »
ПнВтСрЧтПтСбВс
 1
2345678
9101112131415
16171819202122
23242526272829
3031